Prometic Life Sciences PT Raised to C$2.25 (PLI)Prometic Life Sciences PT Raised to C$2.25 (PLI) July 14th, 2014 - 0 comments - Filed Under - by Preston Daniels Share on StockTwits Prometic Life Sciences logoPrometic Life Sciences (TSE:PLI) had its price objective hosited by Canaccord Genuity from C$2.00 to C$2.25 in a report released on Friday. Canaccord Genuity currently has a buy rating on the stock. Canaccord Genuity has also updated their ratings on a number of other stocks in the last week. The firm lowered its price target on shares of Pan American Silver Corp. to $18.50. Also, Canaccord Genuity lowered its price target on shares of Yamana Gold Inc. from C$13.75 to C$13.00. They have a buy rating on that stock. Finally, Canaccord Genuity lowered its price target on shares of Kinross Gold Co. from C$6.75 to C$6.50. They have a buy rating on that stock. Separately, analysts at Paradigm Capital raised their price target on shares of Prometic Life Sciences from C$2.25 to C$2.80 in a research note on Monday, May 12th. They now have a buy rating on the stock. Shares of Prometic Life Sciences (TSE:PLI) remained flat at $1.07 during trading on Friday. The stock had a trading volume of 50,959 shares. Prometic Life Sciences has a 52 week low of $0.355 and a 52 week high of $1.65. The stock has a 50-day moving average of $1.1 and a 200-day moving average of $1.18. The company’s market cap is $565.1 million. ProMetic Life Sciences Inc (TSE:PLI) is a bio-pharmaceutical comnpany offering technologies for large-scale drug purification, drug development, proteomics, clinical diagnostics, and the elimination of pathogens, The Company focuses its activities in two segments: protein technologies and therapeutics.